Tag: durvalumab

Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

Collaboration will evaluate the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab in a Phase 2 neoadjuvant study for patients with head and neck cancer EAGAN, MN — September 5, 2018 — Biothera Pharmaceuticals, Inc. announced today a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab (IMFINZI®) can decrease tumor volume in patients with primary untreated locally...

Read More